Pemazyre Approved for Treatment of Advanced Cholangiocarcinoma
Title: Pemazyre Approved for Treatment of Advanced CholangiocarcinomaCategory: Health NewsCreated: 4/21/2020 12:00:00 AMLast Editorial Review: 4/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 21, 2020 Category: Cancer & Oncology Source Type: news
Pemazyre Approved for Treatment of Advanced Cholangiocarcinoma
MONDAY, April 20, 2020 -- Pemazyre (pemigatinib) has been granted accelerated approval for the treatment of advanced cholangiocarcinoma, the U.S. Food and Drug Administration announced Friday.
The drug approval is indicated for previously treated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2020 Category: General Medicine Source Type: news
FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion
Oncology News burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 20, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves First Targeted Drug for Bile Duct Cancer FDA Approves First Targeted Drug for Bile Duct Cancer
A subgroup of patients with advanced cholangiocarcinma who have tumors with FGFR2 abnormalities have a new treatment option -- the oral targeted therapy pemigatinib.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Pemigatinib for Advanced Cholangiocarcinoma
This is the first FDA approval for this patient population. (Source: CancerNetwork)
Source: CancerNetwork - April 18, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news
FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 17, 2020-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves First Targeted Treatment for Patients with Cholangiocarcinoma, a Cancer of Bile Ducts
FDA has approved Pemazyre (pemigatinib), the first treatment approved for adults with certain types of previously treated, advanced cholangiocarcinoma, a rare form of cancer that forms in bile ducts. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Bile duct cancer: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, Dr. Bret Petersen, a Mayo Clinic?gastroenterologist, discusses bile duct cancer. To listen, click the link below. Bile duct cancer (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 19, 2020 Category: Databases & Libraries Source Type: news
Gravely ill mother diagnosed with bile duct cancer gets new lease of life from revolutionary drug
Mother-of-four Kadiatou Diallo, who is originally from Guinea in West Africa and has lived in the UK for nearly 20 years, is feeling better than she has done in years as a result of taking the new drug. (Source: the Mail online | Health)
Source: the Mail online | Health - March 14, 2020 Category: Consumer Health News Source Type: news
Bile duct cancer treatment potential boost from tailored medication -- study
(University of Birmingham) Treatment of patients suffering from bile duct cancer could be improved by tailoring medication to the levels of a key protein in people with the disease, according to new research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2020 Category: Cancer & Oncology Source Type: news
'Genetic rewiring' drives cancer's drug resistance
(Institute of Cancer Research) Tiny RNA molecule rewires signalling network in bile duct cancer. Drugs to block RNA could overcome cancer's drug resistance. Findings announced to coincide with Bile Duct Cancer Awareness Day. Results could be applicable in other cancer types and have wider benefit. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2020 Category: Cancer & Oncology Source Type: news
Study suggests new strategy for treating advanced, progressing bile duct cancer
(Ohio State University Wexner Medical Center) A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2020 Category: Cancer & Oncology Source Type: news
FDA Grants Priority Review to Pemigatinib for Subgroup
The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
SUZHOU, China, Dec. 1, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ( " Innovent " or " the Company " ) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 1, 2019 Category: Drugs & Pharmacology Source Type: news
Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 27, 2019-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for pemigatinib, a selective... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 27, 2019 Category: Drugs & Pharmacology Source Type: news
